Literature DB >> 1845651

Central nervous system disease in childhood acute lymphoblastic leukemia: prognostic factors and results of treatment.

A Kreuger1, S Garwicz, H Hertz, G Jonmundsson, M Lanning, S O Lie, P J Moe, T T Salmi, H Schröder, M A Siimes.   

Abstract

In the five Nordic countries, 808 children 1 to 15 years of age (428 boys, 380 girls) were diagnosed with non-B acute lymphoblastic leukemia (ALL) from July 1981 through June 1986. Complete remission was achieved in 770 children (95%). Central nervous system (CNS) involvement at diagnosis was noticed in 34 children, of whom 26 achieved remission. Of these 26 patients 11 subsequently relapsed, 5 in the central nervous system. An interim analysis in January 1990 (observation time 3 1/2 to 8 1/2 years) revealed that isolated CNS relapse had occurred in 70 children (9.0%). Of these 70 patients, 12 out of 142 children (8.5%) had initially received irradiation and 58 out of 628 children (9.2%) only chemotherapy as CNS-prophylaxis. There was a significant higher risk for boys (12%) than for girls (6%) to relapse in the CNS compartment. Unfavorable prognostic factors for survival after isolated CNS relapse were short duration of first remission and male sex. In high-risk patients after an isolated CNS relapse, there was no difference in prognosis related to treatment with or without irradiation as initial CNS prophylaxis.

Entities:  

Mesh:

Year:  1991        PMID: 1845651     DOI: 10.3109/08880019109028802

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

Review 1.  Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management.

Authors:  Shilpa Paul; Nicholas J Short
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

2.  Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment.

Authors:  L Vainionpää
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

3.  Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Authors:  R Parameswaran; M Yu; M-A Lyu; M Lim; M G Rosenblum; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2012-02-29       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.